ASTHMA (WJ CALHOUN AND SP PETERS, SECTION EDITORS)

Current Allergy and Asthma Reports

, Volume 13, Issue 5, pp 469-476

First online:

Rationale and Clinical Results of Inhibiting Interleukin-5 for the Treatment of Severe Asthma

  • Rachid BerairAffiliated withDepartment of Respiratory Medicine, Thoracic Surgery, and Allergy, Institute for Lung and Health, Glenfield HospitalDepartment of Infection, Immunity and Inflammation, University of Leicester Medical School
  • , Ian D. PavordAffiliated withDepartment of Respiratory Medicine, Thoracic Surgery, and Allergy, Institute for Lung and Health, Glenfield Hospital Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Severe asthma is responsible for considerable morbidity and a high proportion of the healthcare costs attributable to asthma. Management is not straightforward as the clinical, pathological and physiological features are heterogeneous and the relationships between these features are poorly understood. In recent years significant progress has been made in understanding this heterogeneity and eosinophilic asthma has emerged as a potentially clinically important phenotype because treatment with monoclonal antibodies against IL-5 is effective. This has required a change in our understanding of the role of eosinophilic airway inflammation in airways disease and the developments of reliable biomarkers of eosinophilic airway inflammation. We will review these developments and describe the clinical experience so far with treatment with monoclonal antibiotics against IL-5.

Keywords

Asthma Eosinophils Interleukin-5 IL-5 Inhibiting Inhibition Mepolizumab Severe asthma Treatment